tbuckley/cabot-search huggingface dataset:
Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) for patients with advanced biliary carcinoma as a postoperative adjuvant chemotherapy.
Authors: Yuji Morine, Mitsuo Shimada, Toru Utsunomiya, Satoru Imura, Tetsuya Ikemoto, Jun Hanaoka, Koji Sugimoto, Yu Saito, Shinichiro Yamada, Michihito Asanoma
Journal: Journal of Clinical Oncology (2012)

367 Background: Prognosis of patients with advanced biliary carcinoma is still poor, and chemotherapy has been shown to have little impact. The aim of the present study was to clarify the effectiveness of GEM combined with CDDP and 5FU (GFP) therapy for advanced biliary carcinoma. The usefulness as a postoperative adjuvant chemotherapy using GFP (UMIN000006924) was evaluated. Methods: 1. Identification of independent poor prognostic factors: One hundred one patients with biliary carcinoma before induction of GFP chemotherapy, including intrahepatic cholangiocarcinoma (IHC: n=33), hilar cholangiocarcinoma (HC: n=29), and gallbladder cancer (GBC: n=39) were enrolled. The prognostic factors were investigated by multivariate analysis using Cox’s proportional hazard model. 2. Clinical usefulness of adjuvant GFP chemotherapy: One hundred forty-eight patients with biliary carcinoma (IHC: n=46, HC: n=43, GBC: n=39), who were positive for poor prognostic factors, received postoperative adjuvant GFP chemotherapy. The prognosis of these patients was compared to those not having postoperative adjuvant chemotherapy. Results: 1. In multivariate analysis, non-curative resection, lymph nodes metastasis and intrahepatic metastasis were identified as the independent prognostic factors. 2. Seventy-nine patients (53.3%) had poor prognostic factors. Of these, 22 patients received postoperative adjuvant GFP chemotherapy. The prognosis of patients with poor prognostic factors, who received postoperative adjuvant GFP chemotherapy, was significantly better than those not having such adjuvant chemotherapy (p&lt;0.01) (3y survival: 59.6% vs. 18.9%). Furthermore, in patients with non-curative resection, postoperative adjuvant GFP chemotherapy also prolonged postoperative prognosis (p&lt;0.01) (3y survival: 62.5% vs. 9.4%) Conclusions: Postoperative GFP adjuvant chemotherapy for patients with poor prognostic factors may improve the surgical outcomes.
The Outcome of Lymphoproliferative Disorder in Liver Transplant Recipients May Correlate with Age at Diagnosis and the Use of Chemotherapy: A Single Centre Report.
Authors: Catherine N. Bagot, Austin Kulasekararaj, Sandeep Ramalingam, Nigel Heaton, John O’Grady, Dino Hadzic, Bernard Portmann, Mohamed Rela, Jon Salisbury, Steven Devereux, Ghulam J. Mufti, Antonio Pagliuca
Journal: Blood (2005)
ONO-7643/anamorelin for the treatment of patients with non-small cell lung cancer and cachexia: results from phase 2 study with Japanese patients
Authors: J. Uchino, N. Katakami, T. Yokoyama, T. Naito, M. Kondo, K. Yamada, H. Kitajima, K. Yoshimori, K. Sato, Y. Takiguchi, K. Takayama, K. Eguchi
Journal: Annals of Oncology (2016)
Tracking Senescence In Human Bone Marrow Stromal Cell (BMSC) Cultures.
Authors: Jiaqiang Ren, David Stroncek, Ping Jin, Luciano Castiello, Katherine Tran, Sergei Kuznetsov, Arun Balakumaran, Harvey G Klein, Pamela Robey, Marianna Sabatino
Journal: Blood (2010)
Recommandations of the Societe Francaise des Cancers de l’Enfant (SFCE) for the Management of Tumors Lysis Syndrom (TLS) : A Validation Survey.
Authors: Y. Bertrand, A. Auvrignon, B. Nelken, V. Mialou, F. Mechinaud, B. Brethon, C. Patte, D. Plantaz, M. Urbieta, A. Baruchel, G. Leverger
Journal: Blood (2004)
Second primary cancers and their prognostic significance in patients with renal cell carcinoma.
Authors: R. J. Hauke, S. R. Tarantolo, S. Batra, S. Chakraborty
Journal: Journal of Clinical Oncology (2011)

377 Background: To study the overall and site specific risk and prognostic significance of second primary cancers (SPC) in patients diagnosed with renal cell carcinoma (RCC). Methods: The Surveillance Epidemiology and End Results (SEER) database was queried for all patients with RCC as the first cancer and one or more SPC (1973-2006). SPC diagnosed within 1 month of diagnosis of RCC or at autopsy/death were excluded. Deidentified information was obtained to analyze the effect of SPC on overall survival (OS) of RCC patients. Results: A total of 3,795 patients with RCC and ≥ 1 SPC were identified. The ratio of observed/expected cases (O/E ratio) of RCC and ≥ 1 SPCs was 1.18 (95% C.I. 1.15-1.22), significantly greater than the general population (p&lt;0.05). The overall age-adjusted rate of SPC was 0.6 per 100,000 and rate of SPCs was higher in males and in blacks. The O/E ratio of SPCs was significantly higher in younger patients (6.6 vs. 1.3 and 1.13 for those aged &lt;30, 30-59 and ≥60 yrs respectively), in blacks (1.38 vs. 1.15 in whites), for larger tumors (1.3, 1.2 and 1.05 for tumors &lt;5cm, 5-&lt;10cm and ≥10cm in diameter), and those who did not receive radiation. The risk was similar for both genders. There was variation in the site-specific risk of SPC depending on age at time of RCC diagnosis, gender, race, size of the tumor and presence or lack of radiation therapy. Patients with SPC had longer OS than those with RCC as the only primary tumor on univariate but not multivariate analysis. Older age (≥60yrs), radiation therapy, and a short interval (&lt;12 mo) between the diagnosis of RCC and a SPC were associated with significantly shorter OS in RCC patients with SPC on multivariate analysis. Conclusions: Our comprehensive analysis of SPCs in patients with RCC as the first primary malignancy using SEER data suggests that about 10% of RCC patients develop SPC and that several patient, tumor and treatment-related factors affect the risk of SPC at specific sites. Further, SPC can adversely influence the prognosis of patients with RCC, especially those &gt;60 years old, receiving radiation or diagnosed with a SPC within 1 year after RCC diagnosis. These results may have significance in planning surveillance strategies to improve the survival of patients with RCC. No significant financial relationships to disclose.
Low molecular weight heparin does not prevent VTE after knee arthroscopy, studies show
Authors: Susan Mayor
Journal: BMJ (2016)

Prophylactic treatment with low molecular weight heparin (LMWH) does not prevent symptomatic venous thromboembolism (VTE) in patients who undergo knee arthroscopy or have a leg immobilised in plaster, two randomised studies have shown.1

Patients who have undergone arthroscopic knee surgery and those who have their lower leg in plaster are at increased risk of VTE. Thromboprophylaxis is well established in other types of orthopaedic procedures, including hip and knee replacement surgery, because it reduces the risk of thrombosis while only …
Use of high-resolution fluorescence laparoscopy with fluorophore-conjugated tumor-specific antibodies for the detection of pancreatic cancer metastasis invisible with standard laparoscopy.
Authors: Cristiina A. Metildi, Sharmeela Kaushal, Hop S. Tran Cao, Cynthia S. Snyder, Mark A. Talamini, George A. Luiken, Robert M. Hoffman, Michael Bouvet
Journal: Journal of Clinical Oncology (2012)

212 Background: Standard laparoscopy for pancreatic cancer often leads to false negative results, causing understaging of the disease. Improved sensitivity and resolution are necessary. Methods: Orthotopic and carcinomatosis mouse models of human pancreatic cancer were established with red fluorescent protein (RFP)-expressing or non-fluorescent BxPC-3 human pancreatic cancer cells. The mice with orthotopic unlabeled pancreatic cancer were administered Alexa 488- or 555-conjugated anti-CEA by tail-vein injection 2-4 weeks after tumor implantation. Diagnostic laparoscopy was performed with a Stryker L9000 LED light source or X8000 xenon light source 24 hours later. Pancreatic tumors were detected and localized under each light mode. After laparoscopy, intravital images were obtained with the OV-100 and Maestro CRI Small Animal Imaging Systems as positive controls. Tumors were collected for histologic analysis. Results: Fluorescence laparoscopy (FL) with the use of 495-nm excitation filter and an LED light source enabled more rapid and accurate identification and localization of primary tumors and metastases than bright light laparoscopy (BL). The use of fluorescent conjugates antibody-labeled tumors improved the accuracy of staging laparoscopy, increasing the sensitivity from 40% in BL to 96% in FL (p&lt;0.001). FL was sufficiently sensitive to detect sub-millimeter tumor deposits that went undetected under BL. With adjustments to the LED light source, we could simultaneously detect tumor lesions of different fluorescent colors and surrounding structures with minimal autofluorescence. Conclusions: The use of FL and fluorophore-labeled anti-CEA antibodies permits rapid detection and accurate localization of primary and metastatic CEA-expressing human pancreatic cancer, including tumors that were undetectable with BL. The introduction of an LED light source allows simultaneous identification of fluorescent tumor of different wavelengths without compromising background illumination. Further development of this technology for clinical use can improve the staging and treatment of pancreatic cancer.
Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression
Authors: Anne J. Novak, Takashi Akasaka, Michelle K Manske, Esteban Braggio, Tammy Price-Troska, Steve Ziesmer, Secreto Frank, Rafael Fonseca, Mamta Gupta, Mark E Law, Thomas E. Witzig, Martin JS Dyer, Ahmet Dogan, Ellen McPhail, James R Cerhan, Stephen Ansell
Journal: Blood (2011)
What is the survival length from the late lines of treatment in metastatic breast cancer?
Authors: M. Mouret-Reynier, E. Planchat, E. Thivat, C. Abrial, C. Pomel, P. Dubray-Longeras, H. Devaud, B. Nayl, A. Dillies, Q. Wang-Lopez, P. J. M. Chollet, H. Cure, J. Nabholtz, X. Durando
Journal: Journal of Clinical Oncology (2011)

1121 Background: Metastatic breast cancer (MBC) is an incurable disease in most cases; then treatment is palliative, to prolong overall survival (OS) and control clinical symptoms. Progressively the figures obtained have improved with time. However, the optimal duration of therapy is unknown. Few authors have considered the treatment globally versus for each line and fewer have demonstrated the interest of chemotherapy (CT) after the third line. The aim of this study was to assess tumoral response and OS of patients treated with more than 3 lines of treatment, for each line given. We selected recent patients treated during “taxanes/anti-aromatase era (TAA)” corresponding to an important progress in breast cancer therapy. Methods: Our metastatic database recorded 590 patients with MBC. Among these patients, 530 received at least one line of CT and 383 an hormonotherapy (HT). TAA was defined from December 31th, 1993, as from this date they became available for the french patients. Results: Median OS survival was globally 34.1 months and was calculated for each line given; 226 patients received >3 lines of CT (an increased proportion in comparison with more ancient patients) with a median OS per line rather constant, around 11 months for these late lines. Median OS of women treated with >3 lines of HT was 28 months however, only 70 patients were concerned. Clinical benefit after the third line of CT was obtained for 29.2 to 36.6% of patients and approximately 50% had a progressive disease. Total duration of CT was 11.7 months versus 20.6 months without CT. Conclusions: As the number of available drugs increases, these results support the use of more than 3 lines of CT with a quantifiable benefit in tumoral response and OS. It appears that each line can contribute to a longer survival, when the patient is able to receive it.
Identifying genomic rearrangements in <i>BRCA1</i> and <i>BRCA2</i> in high-risk individuals for hereditary breast and ovarian cancer.
Authors: M. Jackson, D. Mattair, H. Lin, A. M. Gutierrez-Barrera, N. Elsayegh, J. K. Litton, G. N. Hortobagyi, B. Arun
Journal: Journal of Clinical Oncology (2011)

163 Background: Germline mutations in the BRCA1 and BRCA2 genes are responsible for the majority of hereditary breast and ovarian cancer (HBOC). Comprehensive gene sequencing detects ~87% of BRCA mutations, and large genomic rearrangement testing (BART) accounts for ~3%. Criteria have been established to capture individuals who most likely have a BART mutation, however, recent data shows that some individuals have BART mutations and do not meet the criteria. We conducted a single-institution study to evaluate the sufficiency of BART criteria to determine if new criteria are warranted. Methods: During 2006-2008, 172 individuals underwent BRCA sequencing and BART at M. D. Anderson Cancer Center. A retrospective, IRB-approved chart review of a prospectively maintained database was conducted to determine BART criteria eligibility, personal/family history of breast and ovarian cancer and tumor characteristics. Univariate and multivariate analysis was performed to test the significance of each variable in relation to BRCA1/BRCA2 positivity. Results: Of 172 individuals, 12/34 (35%) had BRCA1 BART mutations, and 7/11 (64%) had BRCA2 BART mutations. Of the 19 individuals who tested positive for BART mutations, only 8 (42%) met BART criteria and 11 (58%) did not and proceeded with BART for various reasons (family history, insurance covered, and patient request). Individuals who were BRCA1 positive (sequencing or BART) were more likely to have ER/PR negative breast cancer (p&lt;0.0001) and a personal (p=0.0215)/family history of ovarian cancer (p=0.0001) compared to non-carriers and individuals who had no family history Individuals who were BRCA1 sequencing positive were more likely to meet BART criteria than BRCA1 BART positive (p=0.0151) individuals. Conclusions: Given that no significant differences in family history/tumor characteristics between individuals who have sequencing and BART mutations were identified, and a majority of individuals who were BART positive do not meet BART criteria, it appears that these criteria may be insufficient. BART testing should be considered for all individuals who undergo BRCA sequencing; however, large scale collaboration studies should be conducted.
Clinical Validation of a Physiologically-Based Computer Model of Human Granulopoiesis and Its Use for Improving Cancer Therapy by Doxorubicin and Granulocyte Colony-Stimulating Factor (GCSF).
Authors: Vladimir Vainstein, Yuval Ginosar, Meir Shoham, Anton Ianovski, Alexander Rabinovich, Yuri Kogan, Vera Selitser, Samuel Ariad, Stephen Chan, Zvia Agur
Journal: Blood (2006)
Use of preoperative erythrocyte sedimentation rate (ESR) to predict overall survival in localized renal cell carcinoma following radical nephrectomy.
Authors: V. A. Master, O. Kucuk, W. Harris, B. Cross, A. Abbasi, A. Michigan, A. DeRosa, T. V. Johnson, F. F. Marshall
Journal: Journal of Clinical Oncology (2011)

361 Background: Systemic inflammation has been associated with increased tumor grade and disease progression in renal cell carcinoma (RCC). Erythrocyte sedimentation rate (ESR) reflects systemic inflammation in other disease states. However, the relationship between ESR and survival remains unclear in localized RCC following potentially curative nephrectomy. We hypothesized that preoperative ESR would be a prognostic indicator of overall survival in localized RCC following radical nephrectomy. Methods: 167 patients undergoing nephrectomy for localized RCC had ESR measured preoperatively. Receiver operating characteristics (ROC) curves were constructed and used to determine the area under the curve (AUC) and relative sensitivity and specificity of preoperative ESR in predicting overall survival. From this curve, cut-offs for low risk (0.0-20.0 mm/hr), intermediate risk (20.1-50.0 mm/hr), and high risk (&gt; 50.0 mm/hr) groups were created. Kaplan-Meier analysis was conducted to assess the univariate impact of these ESR-based risk groups on overall survival. Finally, univariate and multivariate Cox regression analysis was conducted to assess the potential of these groups to predict overall survival, adjusting for other patient and tumor characteristics. Results: 55.2%, 27.0% and 17.8% were in the low, intermediate, and high risk groups, respectively. Median (95% CI) survivals for these groups were 44.1 (42.6-45.5), 35.5 (32.3-38.8), and 32.1 (25.5-38.6) months, respectively. After controlling for patient age, race, gender, Charlson Comorbidity Index, T-Stage, Fuhrman Nuclear grade, and tumor size, intermediate risk and high risk groups experienced a 4.5-fold (HR: 4.509, 95% CI: 0.735-27.649) and 18.5-fold (HR: 18.531, 95% CI: 2.117-162.228) increased risk of overall mortality, respectively. Conclusions: Preoperative ESR values represent a robust categorical predictor of overall survival following nephrectomy in localized renal cell carcinoma in this cohort. Clinicians may consider including ESR measurements in counseling patients before nephrectomy, as well as managing patients according to their ESR-based risk category. No significant financial relationships to disclose.
Prostate cancer outcomes and polymorphism in LHRH and LH receptors and SHBG.
Authors: S. Liu, J. K. Pinski, S. A. Ingles
Journal: Journal of Clinical Oncology (2011)

5 Background: The hypothalamic-pituitary-gonadal axis is integral to androgen synthesis and the management of prostate cancer (PC). Genetic variation in the receptors of this pathway may impact the efficiency of signal transduction and overall clinical course. We examined polymorphisms in four receptors central to this pathway: luteinizing hormone-releasing hormone receptor (LHRHR), luteinizing hormone receptor (LHR), androgen receptor (AR) and steroid hormone binding globulin (SHBG). We examined the association between these genotypes and survival. Methods: Patients diagnosed with PC between 1999 and 2004 in Los Angeles County were identified using the Los Angeles County Cancer Registry as part of the California Collaborative Prostate Cancer study, a multiethnic, population based case-control study. Included in this analysis were 1232 men with PC: 631 with advanced stage PC at diagnosis and 430 with high-grade PC. The ethnic breakdown was 376 African-American, 355 Hispanic and 501 Caucasian. DNA was extracted from blood and genotypes for LHR, LHRHR, AR and SHBG were assayed using TaqMan or GeneScan methods. Vital status and cause of death was obtained by linking to the Cancer Registry records. Hazard ratios were estimated by fitting Cox proportional hazards models. Results: As of September 2010, 396 (32%) had died and 122 (10%) had died of PC. In the multivariate model, there was a significant association between disease specific survival and genetic variation in LHRHR, LHR and SHBG. Hazard ratios (HR) for carriers (vs. non-carriers) of the LHR312 minor allele were 1.63 (95% CI: 1.08-2.45) among all cases and 2.04 (1.23-3.39) for high- grade cases. The LHRHR16 minor allele was rare among African Americans; the HR among Caucasians was 1.90 (1.15-3.13) and did not vary by disease grade. The SHGB356 minor allele was associated with survival only among high-grade cases with a HR of 2.38 (1.18-4.81). In addition, when comparing cases to controls, the LHR312 minor allele was inversely associated with PC incidence. Conclusions: Genetic variation in the LHRHR, LHR and SHGB genes are associated with PC survival and warrant further analysis to define their role as prognostic and predictive markers. No significant financial relationships to disclose.
Neoadjuvant rh-endostatin, docetaxel, and epirubicin for breast cancer: Efficacy and safety in a prospective, randomized, phase II study.
Authors: L. Wang, J. Chen, Q. Yao, J. Zhang, T. Wang, H. Wang, X. Zhou, Y. Huan, J. Wang
Journal: Journal of Clinical Oncology (2011)

1132 Background: Rh-endostatin, a protein modified by an additional nine-amino acid sequence to the N-terminal of endostatin, is a novel antiangiogenesis drug developed in China. Previous data suggested that rh-endostatin can inhibit the proliferation and migration of endothelial cells and some types of tumor cells such as lung cancer. In this study, we performed a prospective, randomized, controlled, phase II trial of combining rh-endostatin and neoadjuvant chemotherapy in breast cancer patients to evaluate its efficacy and safety profiles. Methods: Sixty-eight patients with breast cancer were allocated randomly to two groups to receive either 3 cycles of neoadjuvant DE (docetaxel: 75 mg/m2, d1, epirubicin: 75 mg/m2, d1, every 3 weeks), or 3 cycles of neoadjuvant DE and rh-endostatin (7.5mg/m2, d1-d14, every 3 weeks). The primary end point was objective response rate (ORR), and the secondary end point was quality of life (QOL) and toxicity. In addition, the changes of angiogenic profiles involved in tumor response were investigated through contrast-enhanced ultrasonography (CEUS) and contrast-enhanced magnetic resonance imaging (CEMR), and the biological changes were studied by positron emission tomography (PET) pre- and post-neoadjuvant therapy. Results: 64 of 68 (94.2%) patients were assessable for efficacy evaluation. The ORR in the combination and control group was 90.9% (30/33) and 67.7% (21/31), respectively (p = 0.021). Stratification revealed that rh-endostatin was more effective in pre-menopausal and ECOG score of zero patients. Furthermore, rh-endostatin combination induced substantially decreased blood flow in tumor entity, as well as markedly inhibited cell metabolic function. No significant difference was identified in QOL score and side effects (p > 0.05). Conclusions: Compared with DE regimen alone, the combination of rh-endostatin with DE chemotherapy resulted in a higher ORR without increased toxicity in breast cancer patients.